Welcome to our dedicated page for Aim Immunotech news (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on Aim Immunotech stock.
AIM ImmunoTech Inc. (NYSE American: AIM) generates frequent news related to its development of immuno-pharma therapeutics, particularly its flagship product candidate Ampligen (rintatolimod). Company announcements emphasize research and development in cancers, viral diseases, immune-deficiency disorders, and cancers with unmet medical needs, as well as updates on its intellectual property portfolio and corporate actions.
News coverage for AIM ImmunoTech often focuses on clinical and scientific milestones. Recent communications describe progress in the DURIPANC clinical program, where Ampligen is evaluated in combination with AstraZeneca’s Imfinzi (durvalumab) for metastatic pancreatic cancer, and presentations of data from a completed Phase 2 study in advanced recurrent ovarian cancer combining Ampligen with cisplatin and Merck’s Keytruda (pembrolizumab). The company also highlights publications in peer-reviewed journals and abstracts accepted at major scientific meetings such as the Society for Immunotherapy of Cancer (SITC).
Another recurring theme in AIM’s news is the expansion of its intellectual property. The company has announced a European patent covering compositions of its proprietary dsRNAs, including Ampligen, for treating Long COVID, and a patent in Japan for using Ampligen with checkpoint inhibitors for cancer treatment. These updates are presented as part of AIM’s strategy to strengthen protection around Ampligen in oncology and post‑COVID indications.
Investors following AIM ImmunoTech’s news will also see items on financial and corporate developments, including stock dividends, participation in investor conferences, public offerings of common stock and warrants, and financing agreements such as a promissory note with an institutional investor. Regular news releases on quarterly financial results, capital-raising transactions, and shareholder meetings provide additional context on the company’s operations and governance.
This news page aggregates such announcements so readers can review AIM ImmunoTech’s clinical updates, patent developments, financing activities, and corporate communications in one place.
AIM ImmunoTech (OTC Pink: AIMI), an immuno-pharma company specializing in therapeutics for cancers, immune disorders, and viral diseases including COVID-19, has announced its transition to trading under the ticker AIMI on the Pink Open Market effective April 07, 2025.
The company also confirmed its upcoming Special Meeting scheduled for April 30, 2025, where a reverse split proposal will be discussed. Shareholders can find detailed information in AIM's Definitive Proxy Statement filed on April 2, 2025.
AIM ImmunoTech (NYSE American: AIM), an immuno-pharma company focused on cancer, immune disorders, and viral diseases therapeutics, announced receiving a delisting notification from NYSE American on April 4, 2025. The Exchange suspended trading of AIM's common stock due to its low selling price, citing Section 1003(f)(v) of the NYSE American Company Guide.
The company plans to appeal the determination to the Exchange's Listing Qualifications Panel, though success is not guaranteed. Trading of AIM's common stock is expected to transition to the Pink Open Market starting April 7, 2025.
AIM ImmunoTech (NYSE: AIM) has reported its Q4 and full year 2024 financial results, highlighting progress in its Ampligen clinical development programs. The company ended 2024 with $4.0 million in cash and investments, down from $13.1 million in 2023. Financial metrics show reduced expenses, with R&D costs decreasing to $6.2 million from $10.9 million and G&A expenses dropping to $13.7 million from $21.1 million year-over-year.
Key developments include the advancement of the DURIPANC Phase 1b/2 trial combining Ampligen with AstraZeneca's Imfinzi for late-stage pancreatic cancer, and upcoming milestones in multiple clinical trials through 2026. The company is also pursuing studies in refractory melanoma, triple negative breast cancer, and advanced recurrent ovarian cancer, with several trials being partially funded by collaborators including AstraZeneca and Merck.
AIM ImmunoTech (NYSE American: AIM) participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference on March 11, 2025. CEO Thomas K. Equels presented five key focus areas for 2025:
- Progress in late-stage pancreatic cancer treatment through the Phase 1b/2 DURIPANC trial at Erasmus Medical Center, Netherlands
- Expanded research in ME/CFS and post-COVID conditions
- Advancement of oncology pipeline with trials reaching major milestones
- Development of Ampligen as a vaccine adjuvant for bird flu
- Ampligen's potential as a broad-spectrum immunotherapy
The presentation is available on-demand through the company's website and investor events page.
FAQ
What is the current stock price of Aim Immunotech (AIM)?
What is the market cap of Aim Immunotech (AIM)?
